Recurrent Vaginal Infections with Odor and Discharge: Evidence-Based Evaluation, Causes, and Treatment Options

Recurrent vaginal infections presenting with odor and discharge are common reasons for gynecologic visits and can reflect several overlapping conditions. The term “recurrent” typically indicates repeated episodes over time, often requiring a differential diagnosis that distinguishes reinfection from treatment failure, incomplete eradication, or an underlying host-factor (such as diabetes, immunosuppression, hormonal shifts, or anatomic issues). The characteristic triad in the prompt—odor, discharge, and recurrent symptoms—points most strongly to disorders that alter the vaginal microbiome and vaginal epithelial environment.

The vaginal ecosystem is dominated by Lactobacillus species in most healthy reproductive-age individuals. These organisms maintain low vaginal pH through lactic acid production and create colonization resistance against pathogenic organisms. When the microbiome is disrupted, symptoms may include increased discharge, changes in odor, burning or irritation, and sometimes pelvic discomfort. Clinically, three major categories account for many cases: bacterial vaginosis (BV), vulvovaginal candidiasis (yeast infection), and trichomoniasis or other sexually transmitted infections (STIs). Less common but important considerations include aerobic vaginitis, desquamative inflammatory vaginitis, cytolytic vaginosis, retained foreign body, cervicitis, and noninfectious etiologies such as contact dermatitis.

Bacterial vaginosis is associated with a shift away from Lactobacillus dominance toward mixed anaerobic bacteria (e.g., Gardnerella vaginalis and others). BV often produces a thin, gray-white discharge and a “fishy” odor, especially after sexual intercourse. Vaginal pH is typically elevated (commonly >4.5). BV is not classified as an STI, but sexual activity can influence risk by promoting microbiome changes. Recurrence is frequent, which is why evaluating for persistent dysbiosis and adherence to treatment is critical.

Vulvovaginal candidiasis typically causes thicker discharge (classically “cottage cheese” in appearance) with intense pruritus and vulvar erythema. Odor is not always prominent, but patients may describe an unpleasant smell due to inflammation and secondary irritation. Candida albicans is common; non-albicans Candida species may require different antifungal strategies because of possible reduced responsiveness to standard azoles. Recurrent vulvovaginal candidiasis is generally defined clinically as four or more symptomatic episodes in a year.

Trichomoniasis, caused by Trichomonas vaginalis, can present with frothy discharge, vaginal odor, and irritation. It is sexually transmissible and is associated with an increased risk of acquiring or transmitting other STIs, including HIV. Persistent or recurrent symptoms should prompt STI testing and partner evaluation.

Evaluation should be systematic and evidence-based. Clinicians often perform a history (timing, triggers, sexual exposure, contraception, hygiene practices, prior treatments), a focused pelvic exam, and bedside diagnostics such as vaginal pH testing, saline microscopy (wet mount), and whiff test. For uncertain cases or recurrent disease, nucleic acid amplification tests (NAATs) for STIs (including trichomoniasis and chlamydia/gonorrhea) and specific testing for Candida species may be warranted. When symptoms persist despite therapy, consider antimicrobial resistance, reinfection, adherence issues, and noninfectious mimics.

Treatment depends on the confirmed etiology. BV is commonly treated with metronidazole or clindamycin regimens; candidiasis is treated with azoles (topical or oral), with longer courses for complicated or recurrent disease; and trichomoniasis requires antitrichomonal therapy, with treatment of sexual partners to prevent reinfection. For recurrence, clinicians may consider maintenance strategies (e.g., intermittent antifungal dosing for recurrent yeast, or suppressive regimens in selected BV cases) and address modifiable risk factors.

Concerning “herbal remedies”: patients frequently seek nonprescription options for odor and discharge. However, most herbal products lack robust clinical trial evidence, may be inconsistently formulated, and can sometimes irritate vulvar tissue or worsen dysbiosis. Some agents may have antimicrobial activity in vitro but fail to demonstrate effectiveness in humans or may not target the specific microbiologic mechanism. Therefore, herbal interventions should not replace diagnostic evaluation and guideline-based therapy, especially when symptoms recur or when STI risk is possible. If patients choose to use complementary approaches, it is prudent to do so only alongside medical assessment, and to avoid intravaginal products that can disrupt the mucosal barrier.

Preventive strategies center on restoring and maintaining microbiome stability. Avoiding unnecessary douching, minimizing harsh soaps, and using gentle, unscented cleansing practices help preserve the vaginal mucosa. Condom use can reduce STI transmission risk and may lower recurrence risk for BV in some contexts. In recurrent disease, clinicians may evaluate for underlying conditions such as diabetes, evaluate medication effects (e.g., steroids or antibiotics), and discuss sexual practices that correlate with symptom flares. Probiotic strategies have mixed evidence; any use should be framed as adjunctive rather than definitive.

Red flags include fever, pelvic pain, pregnancy, severe or worsening symptoms, blood in discharge, new sexual partners with STI risk, and failure to improve after appropriate therapy—each requiring timely medical reassessment. Recurrent odor and discharge are medically meaningful because they often signify persistent microbial imbalance, an untreated STI, or an inflammatory condition needing targeted management.

Source: @womenFit_